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Idiopathic pulmonary fibrosis (IPF) is the commonest cause of interstitial lung disease. Till date
there is no proven successful treatment. The prognosis is poor with a median survival of 3
years. Patients with IPF presented with acute respiratory failure are often referred to the
intensive care unit for ventilatory support. Available data showed that outcome of these
patients is very poor and mechanical ventilation is mostly futile. Patients and their families
should be informed about the prognosis, outcome and overall outlook before making decision
about ventilation and organ support. Available outcome data should be used to develop insti-
tutional and professional guidelines to help in making these difficult decisions.
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1356 S. MallickIntroduction
Idiopathic pulmonary fibrosis is the commonest form of
interstitial lung disease (ILD). It is a progressive chronic
disease of uncertain aetiology characterized by inflamma-
tion and fibrosis of lung parenchyma affecting gas
exchange. Prognosis is poor with median survival of 3 years
irrespective of treatment. IPF appears to be much more
prevalent than previously reported. One previous study has
reported an incidence of 6.8 per 100,000 in the United
Kingdom, in 2000e2003.1,2Clinical features and diagnosis
Clinical features of IPF consist of progressive dyspnoea,
hypoxia with cyanosis, clubbing and end inspiratory
crackles at the lung bases.
Reticular shadowings are seen on chest radiograph.
Characteristic CT scan findings include reticular opacities,
traction bronchiectasis and in advanced stages honeycomb-
ing and volume loss are prominent. Lung function test
suggests restrictive defect with impaired gas exchange.
Although diagnosis is confirmed by lung biopsy representing
usual interstitial pneumonia, thoracoscopic or open lung
biopsy is not necessary in presence of characteristic clinical
and radiological findings.5 Unfortunately there is no proven
successful treatment. Corticosteroids and immunosuppres-
sants have not shown any significant benefit.27,28 As the
disease progresses therapeutic intervention is mainly palli-
ative. The only treatment proven effective in prolonging
survival is lung transplantation. As patients with IPF are
usually elderly and most centres limit lung transplantation
to those <65 yr of age due to increased mortality risk29 it
is limited to minority of patients.
According to the joint statement5 of the American Tho-
racic Society (ATS) and the European Respiratory Society
(ERS), presence of all of the following major diagnostic cri-
teria as well as at least 3 of the 4 minor criteria increases
the likelihood of correct clinical diagnosis of IPF. The Major
Criteria include (1) exclusion of other known causes of ILD,
such as drug toxicities, environmental exposures, and con-
nective tissue diseases, (2) abnormal pulmonary function
studies that include evidence of restriction and impaired
gas exchange, (3) bibasilar reticular abnormalities with
minimal ground-glass opacities on HRCT scans and (4) trans
bronchial lung biopsy or bronchoalveolar lavage (BAL)
showing no features to support an alternative diagnosis.
The Minor Criteria include (1) age> 50 yr, (2) insidious
onset of otherwise unexplained dyspnoea on exertion,
(3) duration of illness 3 months and (4) bibasilar, inspira-
tory crackles (dry or ‘Velcro’ type in quality).
Acute deterioration
Clinical course of IPF is usually chronic and slowly pro-
gressive3e5 but acute deterioration may occur secondary to
infections, pulmonary embolism, pneumothorax, or heart
failure.6 It may also occur in half of these patients without
an identifiable cause, when it is attributed to acute exacer-
bation of IPF.7,8 Acute exacerbations are defined by anacute onset of dyspnoea (less than 1 month) with worsening
hypoxia and progressive bilateral radiographic infiltrates
seen in the absence of reversible causes.7,9 New ground-
glass infiltrates are seen on chest CT scans and diffuse
alveolar damage superimposed on a background of usual
interstitial pneumonia is evident on histopathology.
In a retrospective review10 of a cohort of 147 patients
with IPF, 2-year incidence of acute exacerbation was
reported at 9.6%, and mortality at 78%. The time to devel-
opment of acute exacerbation from the subjects’ initial
visits was between 3 and 60 months.
Several case reports30,31 have suggested that acute
exacerbation can be precipitated by surgical lung biopsy
or bronchoalveolar lavage. In their retrospective study
Kondoh et al.33 identified 5 patients (2.1%) among 236
patients with ILD who developed acute exacerbation fol-
lowing surgical lung biopsy. The unexpected finding in
that study was the increased and significantly greater
parenchymal involvement on HRCT scan of the nonoper-
ated lung in comparison to the operated lung and preoper-
ative scans. This suggests factors other than surgery which
includes hyperoxygenation during single lung ventilation,
overdistension, ventilator associated lung injury, etc.
may play a role in postoperative acute exacerbation. No
studies have compared operative time, anaesthesia used,
or the percentage of oxygen used to determine whether
these variables are risk factors.9 Mortality rate in patients
who develop postoperative acute exacerbation is 50% or
greater.32
Outcome from mechanical ventilation
Majority of patients with IPF are admitted in intensive care
with acute respiratory failure. It is always difficult to make
a decision of not to ventilate a patient referred for acute
respiratory failure. There is conflict of opinion between
physicians and intensivists criticising each other which
ranges from inappropriate referral to prognostic
pessimism.
Decision of not to ventilate usually depends on assess-
ment of futility of care depending on poor short-term
prognosis, patients wishes and the high probability of
poor quality of life in the future. Before making such
decision doctors usually try to look for evidence on previous
outcomes in similar cases.
Evidence
A review of the literature was performed utilizing MEDLINE
(via PubMed) and internet searches using key words e
idiopathic pulmonary fibrosis, ventilation, outcome, and
intensive care unit. Additionally, the European Respiratory
Society, American Thoracic Society, and American College
of Chest Physicians sites were searched for relevant
abstracts. Study, patient numbers, age and outcomes
were extracted from accepted studies (Table 1). The
main outcome measure was mortality in intensive care
and short-term mortality (within 3 months of hospital
discharge).
Figures represent absolute numbers. Short-term mortal-
ity indicates mortality within 3 months of hospital discharge.
Table 1 Outcome studies on IPF patients ventilated in ICU
Study (period observed) Number of
IPF patients
ventilated
Age Number having
histological
confirmation of UIP
Hospital
mortality
Overall
short-term
mortality
Blivet et al.,11 France (1989e1998) 15 64 10 7 11 13
Molina-Molina et al.,12 Spain (1986e2002) 14 e e 14 14
Saydain et al.,13 USA (1995e2000) 19 68.3 11.5 9 11 17
Nava and Rubini,14 Italy 7 e 7 6 6
Stern et al.,15 France (1991e1999) 23 52.9 mean 8 22 22
Al-Hameed and Sharma,16 Canada (1988e2000) 25 69 11 e 24 24
Fumeaux et al.,17 Switzerland (1996e2001) 11 72 8.2 4 11 11
Kim et al.,10 South Korea (1990e2003) 9 63.4 6.3 9 7 8
Pitsiou et al.,18 Greece (2001e2005) 12 63 12 e 12 12
Total 135 51 118 127
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Nine studies consisting of 135 patients with established
diagnosis of IPF fulfilled the criteria for inclusion in the
analysis. Patients those who were ventilated in intensive
care are only included from these studies. Adding the
individual mortality data from these studies the pooled
data showed an aggregated mortality of 118 (87%) among
135 IPF patients ventilated in intensive care units. The
short-term mortality (mortality within 3 months of hospital
discharge) is 127 (94%). The mean duration of mechanical
ventilation was 8.6 days. Of the very few patients who
survived, respiratory failure was precipitated by surgery/
anaesthesia in 2 patients, 1 had undergone lung transplant
and 3 patients were lost in follow-up.
Two of these studies (Al-Hameed and Nava et al.)
included patients where no reversible cause was found for
acute respiratory failure. In one study (Fumeaux et al.)
infection was presumed to be the precipitating cause in all
the patients (nZ 11). Of the remaining 92 patients e 30
had respiratory infection (bacterial and fungal), 5 pneumo-
thorax, 4 congestive heart failure, and 2 pulmonary embo-
lisms. Four patients developed respiratory failure following
bronchoalveolar lavage, biopsy and anaesthesia. In 47
patients no precipitating factor for acute respiratory failure
was found.
Exceptions (post operative respiratory failure)
A recent retrospective study involving 94 patients with ILD
(of which 30 patients had IPF who were ventilated, Evans
et al.19 reported that 40% of patients with IPF survived to
hospital discharge. The results are encouraging but a signif-
icant number of patients (43.6%) in this study were admit-
ted following a surgical procedure where respiratory
failure was likely to be precipitated by operative and
anaesthetic complications rather than pulmonary fibrosis
itself. As these patients were considered for elective sur-
gery they were likely to have better performance status
and reasonably stable pulmonary function than patients in
the other studies. Seventy percent of the survivors were
postsurgical patients. If we exclude this group of patientsthe mortality will reach nearly 90% in the remainder, similar
to the other studies.
Operative mortality is low in IPF patients who undergo
surgical lung biopsy for diagnostic evaluation.35,36 Patients
requiring mechanical ventilation,35 elderly, presenting
with atypical features and low diffusion capacity34 are asso-
ciated with an increased risk of death following lung biopsy.
Chiyo et al.20 investigated the postoperative morbidity
and mortality of patients with lung cancer and ILD. The
30-day mortality was only 2.8%. Similarly, Martinod
et al.21 observed no postoperative deaths in 27 patients
with ILD undergoing lung cancer resection. This group of
patients should be considered for ventilation like any other
postsurgical patient as the condition is reversible and
should not be denied life support because of underlying IPF.
Ventilatory setting
In most of the above studies the mode of ventilation used
was not mentioned. In their recently published observa-
tional cohort study Ferna´ndez-Pe´rez and colleagues showed
that high positive end expiratory pressure (PEEP) setting is
associated with worse outcome. Patients with IPF has little
or no recruitable lung and high PEEP is likely to cause
overdistension of relatively intact lung leading to ventila-
tor-induced lung injury (VILI). When invasive ventilation has
to be used in IPF patients, like postoperative patients,
patients with reversible cause of acute deterioration or
where diagnosis has not been established, low tidal volume
and low (PEEP) should be employed regardless of the mode
of ventilation (volume controlled or pressure controlled).
Discussion
Kondoh et al.7 in 1993 described 3 IPF patients with fea-
tures of acute exacerbation. Subsequently diagnostic crite-
ria as described above are used to identify similar patients
with acute exacerbation. Many of the studies in this review
included patients when the term acute exacerbation was
not recognised and their condition was described as acute
respiratory failure of unknown aetiology or progression of
IPF. In retrospect when we look at these studies like that
1358 S. Mallickof Saydian et al. where in 7 out of 10 patients no organisms
recovered from BAL and histology of 6 out of 9 patients
showed features of diffuse alveolar damage, these indicate
that a significant number of these patients did have acute
exacerbation of IPF.
Patients with IPF admitted to ICU with acute respiratory
failure needing ventilation have very poor prognosis.
Mechanical ventilation and life support do not seem to
have any effect on mortality. Management plan should
include early investigations including CT scan, echocardio-
gram, BAL, infection screen, etc. to look for reversible
causes like pneumothrax, infection, heart failure, pulmo-
nary embolism and to treat the cause. If these tests are
negative the deterioration is attributed to acute exacerba-
tion and be treated according to local protocol (Methyl
prednisolone with Cyclophosphamide or other immunosu-
pressants) till newer drugs with proven benefit arrives. If
early intervention fails, these data suggest that outlook for
survival is very poor. Mechanical ventilation is futile and
patients and their families should be informed about the
prognosis, outcome and overall outlook before making
decision about ventilation and ITU care. Clinicians should
be prepared to discuss the outcome of life support
compared to comfort and palliative care with patients
when they see them in an earlier stage in the clinic and
document in the notes accordingly. During acute admission
the risks of ventilation and the chance of surviving should
be addressed if it was not done before. Most of the time this
is not done before these patients are transferred to
intensive care unit when it is more difficult to explain this
to them and their relatives.
Intensivists should not deny life support to stable IPF
patients who went into respiratory failure following a sur-
gical procedure. They also need to remember that all
interstitial lung disease patients are not IPF and non-IPF
ILDs (like nonspecific interstitial pneumonia, respiratory
bronchiolitis-associated interstitial lung disease, desqua-
mative interstitial pneumonia, cryptogenic organizing
pneumonia, etc.) have a better prognosis.
Physicians, intensivists, and ethisists all agree that futile
and in appropriate treatment should not be initiated even
when it is requested.22 Unfortunately there is considerable
difference in opinion between clinicians regarding appro-
priateness of treatment for similar patients.23 Several
authors24e26 have suggested that available outcome data
should be used to develop institutional and professional
guidelines to help in making these difficult decisions.Summary points
 IPF is the commonest cause of interstitial lung disease
with a median survival of 3 years, which is worse than
many cancers.
 No treatment for IPF till date proven effective except
lung transplant, which is limited to minority of
patients.
 Acute deterioration may occur secondary to infections,
pulmonary embolism, pneumothorax, or heart failure.
 It may also occur in half of these patients without an
identifiable cause, when it is attributed to acute exac-
erbation of IPF. Management plan should include early investigations
including CT scan, echocardiogram, BAL, infection
screen, etc. to look for reversible causes.
 Available data showed that outcome of these patients
in ICU is very poor and mechanical ventilation is mostly
futile.
 Postsurgical patients with respiratory failure have
better survival as the precipitating condition is likely
reversible. They should not be denied life support
because of underlying IPF.
 All the above data is from patients with IPF. Non-IPF
ILDs have a better prognosis and should not be denied
ventilation based on the above data.Conflict of interest statement
No conflict of interest in relation to this review.
References
1. Gribbin J, Hubbard RB, Le Jeune I, Smith CJP, West J, Tata LJ.
Incidence and mortality of idiopathic pulmonary fibrosis and
sarcoidosis in the UK. Thorax 2006;61:980e5.
2. Wells AU, Cory M. Hogaboam update in diffuse parenchymal
lung disease. Am J Respir Crit Care Med 2007;175:655e60.
3. Turner-Warwick MB, Burrows AJ. Cryptogenic fibrosingalveoli-
tis: clinical features and their influence on survival. Thorax
1980;35:171e80.
4. Carrington CB, Gaensler EA, Coutu RE, Fitzgerald MX,
Gupta RG. Natural history and untreated course of usual and
desquamative interstitial pneumonia. N Engl J Med 1978;298:
801e9.
5. American Thoracic Society. Idiopathic pulmonary fibrosis:diag-
nosis and treatment: international consensus statement. Am J
Respir Crit Care Med 2000;161:646e64.
6. Panos RJ, Mortenson RL, Niccoli SA, King TE. Clinical deteriora-
tion in patients with idiopathic pulmonaryfibrosis: causes and
assessment. Am J Med 1990;4:396e404.
7. Kondoh Y, Taniguchi H, Kawabata Y, Yokoi T, Suzuki K, Takag K.
Acute exacerbation in idiopathic pulmonary fibrosis. Analysis
of clinical and pathologic findings in three cases. Chest 1993;
103:1808e12.
8. Tsukamoto K, Chida K, Hayakawa H, Sato A, Nakajima Y,
Doi O, et al. Prediction of outcome after acute exacerbation
of idiopathic interstitial pneumonia. Nihon Kyobu Shikkan
Gakkai Zasshi 1997;35:746e54.
9. Hyzy R, Huang S, Myers J, Flaherty K, Martinez F. Acute exac-
erbation of idiopathic pulmonary fibrosis. Chest 2007;132:
1652e8.
10. Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby T. Acute
exacerbation of idiopathic pulmonary fibrosis: frequency and
clinical features. Eur Respir J 2006;27:143e50.
11. Blivet S, Philit F, Sab JM, Langcvin B, Paret M, Guerin C, et al.
Outcome of patients with idiopathic pulmonary fibrosis admit-
ted to the ICU for respiratory failure. Chest 2001;120:209e12.
12. Molina-Molina M, Badia JR, Marı´n-Arguedas A, Xaubet A,
Santos MJ, Nicola´s JM, et al. Outcomes and clinical character-
istics of patients with pulmonary fibrosis and respiratory failure
admitted to an intensive care unit. A study of 20 cases. Med
Clin (Barc) 2003;121(2):63e7.
13. Saydain G, Islam A, Afessa B, Ryu JH, Scott JP, Peters SG. Out-
come of patients with idiopathic pulmonary fibrosis admitted
to the intensive care unit. Am J Respir Crit Care Med 2002;
166:839e42.
Outcome of patients with idiopathic pulmonary fibrosis 135914. Nava Stefano, Rubini Fiorenzo. Lung and chest wall mechanics
in ventilated patients with end stage idiopathic pulmonary
fibrosis. Thorax 1999;54:390e5.
15. Stern JB, Mal H, Groussard O, Brugiere O, Marceau A, Jebrak G,
et al. Prognosis of patients with advanced idiopathic pulmo-
nary fibrosis requiring mechanical ventilation for acute respira-
tory failure. Chest 2001;120:213e9.
16. Al-Hameed FM, Sharma S. Outcome of patients admitted to the
intensive care unit for acute exacerbation of idiopathic pulmo-
nary fibrosis. Can Respir J 2004;11:117e22.
17. Fumeaux T, Rothmeier C, Jolliet P. Outcome of mechanical
ventilation for acute respiratory failure in patients with pulmo-
nary fibrosis. Intensive Care Med 2001;27:1868e74.
18. Pitsiou G, Trigonis I, Tsiata E, Kontou P, Manolakoglou N,
Stanopoulos I, et al. Argyropoulou (Thessaloniki, Greece) out-
come of patients with pulmonary fibrosis admitted to the ICU
for acute respiratory failure. Eur Respir J 2006;(28 Suppl.).
19. Ferna´ndez-Pe´rez ER, Yilmaz M, Jenad H, Daniels CE, Ryu JH,
Hubmayr RD, et al. Ventilator settings and outcome of respira-
tory failure in chronic interstitial lung disease. Chest, doi:
10.1378/chest.07-1481.
20. Chiyo M, Sekine Y, Iwata T, Tatsumi K, Yasufuku K, Iyoda A, et al.
Impact of interstitial lung disease on surgical morbidity and
mortality for lung cancer: analyses of short-term and long-
term outcomes. J Thorac Cardiovasc Surg 2003;126:1141e6.
21. Martinod E, Azorin JF, Sadoun D, Destable MD, Le Toumelin P,
Longchampt E. Surgical resection of lung cancer in patients
with underlying interstitial lung disease. Ann Thorac Surg
2002;74:1004e7.
22. Withholding and withdrawing life-sustaining therapy. This Offi-
cial Statement of the American Thoracic Society was adopted
by the ATS Board of Directors, March 1991. Am Rev Respir Dis
1991;144(3 Pt 1):726e31.
23. Cook DJ, Guyatt GH, Jaeschke R, Reeve J, Spanier A, King D,
et al. Determinants in Canadian health care workers of the de-
cision to withdraw life support from the critically ill. Canadian
Critical Care Trials Group. JAMA 1995;273:703e8.
24. Alpers A, Lo B. When is CPR futile? [Editorial]. JAMA 1995;273:
156e8.25. Murphy DJ, Finucane TE. New do-not-resuscitate policies. A first
step in cost control. Arch Intern Med 1993;153:1641e8.
26. Rubenfeld GD, Crawford SW. Withdrawing life support from
mechanically ventilated recipients of bone marrow trans-
plants: a case for evidence-based guidelines. Ann Intern Med
1996;125:625e33.
27. Davies HR, Richeldi L, Walters EH. Immunomodulatory agents
for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev
2003;(3):CD003134. doi:10.1002/14651858.CD003134.
28. Richeldi L, Davies HR, Ferrara G, Franco F. Corticosteroids for
idiopathic pulmonary fibrosis. Cochrane Database Syst Rev
2003;(3):CD002880. doi:10.1002/14651858.CD002880.
29. Gutierrez C, Al-Faifi S, Chaparro C, Waddell T, Hadjiliadis D,
Singer L, et al. The effect of recipient’s age on lung transplant
outcome. Am J Transplant 2007;7(5):1271e7.
30. Hiwatari N, Shimura S, Takishima T, Shirato K. Bronchoalveolar
lavage as a possible cause of acute exacerbation in idiopathic
pulmonary fibrosis patients. Tohoku J Exp Med 1994;174:
379e86.
31. Tasaka S, Kanazawa M, Komune Y, Soejima K, Hirakata M,
Yamaguchi K, et al. Acute exacerbation of subacute interstitial
pneumonia after thoracoscopic lung biopsy. Nihon Kokyuki
Gakkai Zasshi 1998;36:182e6.
32. Hoshikawa Y, Kondo T. Perioperative lung injury: acute exacer-
bation of idiopathic pulmonary fibrosis and acute interstitial
pneumonia after pulmonary resection. Nippon Geka Gakkai
Zasshi 2004;105:757e62.
33. Kondoh Y, Taniguchi H, Kitaichi M, Yokoi T, Johkoh T, Oishi T,
et al. Acute exacerbation of interstitial pneumonia following
surgical lung biopsy. Respir Med 2006;100:1753e9.
34. Utz JP, Ryu JH, DouglasWW, HartmanTE, Tazelaar HD,Myers JL,
et al. High short-term mortality following lung biopsy for usual
interstitial pneumonia. Eur Respir J 2001;17:175e9.
35. Lettieri CJ, Veerappan GR, Helman DL, Mulligan CR, Shorr AF.
Outcomes and safety of surgical lung biopsy for interstitial
lung disease. Chest 2005;127:1600e5.
36. Tiitto L,HeiskanenU,BloiguR,Pa¨a¨kko¨ P, KinnulaV,Kaarteenaho-
Wiik R. Thoracoscopic lung biopsy is a safe procedure in diagnos-
ing usual interstitial pneumonia. Chest 2005;128:2375e80.
